Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 

Abstract/Editors' Note | Full Text | PDF

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis



View larger version (24K):

[in a new window]
 
Figure. Progression of persons screened for diabetes. *Diabetes onset; {dagger}Diabetes diagnosis by screening; {ddagger}Diabetes diagnosed clinically.

 


View larger version (24K):

[in a new window]
 
Appendix Figure 1. Markov model of diabetes disease progression. The model is used to follow the disease progression of all members of a cohort simultaneously on 5 different disease paths. At the end of any period, the cohort occupies one state on each of the disease paths. For the simulation, transitions between states take place at discrete time intervals 1 year apart. Thus, at the end of each 1-year period, portions of the cohort can move from one disease state to another or stay in the same disease state. The simulation program determines what proportion of the cohort will move from one state to another on the basis of the transition probability. In several cases, an individual can experience a complication event that the patient either dies of or survives during the period. The Markov model keeps track of the number of patients who are in each state in each period. It also tracks the cumulative incidence of patients who have undergone complication events, such as lower-extremity amputation (LEA), angina, cardiac arrest (CA) or myocardial infarction (MI), and stroke. In the diagrams, complication events are represented by diamonds; states are numbered and represented by ovals. CHD = coronary heart disease. ESRD = end-stage renal disease.

 

View this table:

[in a new window]
 
Table 1. Number of Screenings and Diagnostic Tests Needed To Identify One Undiagnosed Diabetes Case

 

View this table:

[in a new window]
 
Table 2. Targeted Screening for People with Hypertension Only, with Intensive Glycemic Control and Intensified Hypertension Control after Diagnosis

 

View this table:

[in a new window]
 
Table 3. Universal Screening with Intensive Glycemic Control and Intensive Hypertension Control after Diagnosis

 

View this table:

[in a new window]
 
Table 4. Incremental Cost-Effectiveness Ratios for Diabetes Screening

 

View this table:

[in a new window]
 
Table 5. Sensitivity Analyses

 

View this table:

[in a new window]
 
Appendix Table 1. Base Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Diabetes Screening

 

View this table:

[in a new window]
 
Appendix Table 2. Discount Rates

 

View this table:

[in a new window]
 
Appendix Table 3. Base-Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Nephropathy

 

View this table:

[in a new window]
 
Appendix Table 4. Base-Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Neuropathy

 

View this table:

[in a new window]
 
Appendix Table 5. Base-Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Retinopathy

 

View this table:

[in a new window]
 
Appendix Table 6. Base-Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Coronary Heart Disease

 

View this table:

[in a new window]
 
Appendix Table 7. Base-Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Stroke

 

View this table:

[in a new window]
 
Appendix Table 8. Base-Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Standard Glycemic Control

 

View this table:

[in a new window]
 
Appendix Table 9. Base-Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Tight Glycemic Control

 

View this table:

[in a new window]
 
Appendix Table 10. Base-Case Values and Distributions Applied in Probabilistic Sensitivity Analysis for Selected Parameters: Hypertension Control

 


View larger version (17K):

[in a new window]
 
Appendix Figure 2. Histograms of cost-effectiveness ratios resulting from probabilistic sensitivity analyses based on targeted (top) and universal (bottom) screening. A probabilistic sensitivity analysis was conducted in which 129 critical parameters were simultaneously varied over probability distributions on the basis of published 95% CIs or other reasonable ranges. A cost-effectiveness ratio was computed for each of 1000 iterations for both targeted and universal screening of people age 55 years. QALY = quality-adjusted life-year.

 





 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2004 by the American College of Physicians.